Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer

Next Previous
Trial Profile

A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Tamoxifen
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ATAC
  • Sponsors AstraZeneca

    • Most Recent Events

    • 31 May 2020 Results (n=818, TransATAC patients)analysing the prognostic value of StemPrintER Risk Score (SPRS) in the TransATAC cohort of post-menopausal ER+/HER2- BC patients, and compare the prognostic information provided by SPRS and OncotypeDX Recurrence Score (RS) for 10-year risk of distant metastasis (DM), presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 14 Dec 2019 Results evaluating correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index in TransATAC tumour sample set, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
    • 05 Jun 2012 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.(NCT00849030).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top